Adam Brufsky, MD, PhD, on the Potential Role of Neratinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer

Posted: Monday, July 29, 2019

Adam Brufsky, MD, PhD, of Magee-Womens Hospital and the Hillman Cancer Center at the University of Pittsburgh Medical Center, discusses the potential role of the combination therapy neratinib plus capecitabine in the later-line treatment of women with HER2-positive metastatic breast cancer, based on the phase III NALA trial results.